Time Horizon

12 months. CF is a cyclical commodity producer trading at Hormuz-premium levels. The relevant question is whether nitrogen prices sustain through 2026 or revert to mid-cycle. Key forcing functions: Hormuz resolution (unknown timeline), spring planting (inelastic demand through June), Q1 earnings (May 6), Blue Point milestones (2026-2029). The 45Q credit ramp is a 3-5 year story subordinate to the 12-month nitrogen cycle.

Base Rate

Base rate: Commodity producer at +82% 1Y momentum → 25-30% revert within 12 months
Prior odds: 0.35 (outperform from here)

Reference class: large-cap commodity producers trading 35%+ above consensus target after a supply-shock-driven rally. Historical pattern: the commodity superspike premium (fertilizer 2022, energy 2022, uranium 2007) typically overshoots by 30-50%, then reverts as supply adjusts or geopolitical risk reprices. CF traded to $142 in Feb 2022 on the Russia/Ukraine fertilizer spike, then to $71 by late 2024. The current Hormuz-driven rally to $142 (before pulling back to $130) rhymes.

Alpha vs Beta

Total 1Y return:                    +82%
  Market beta (0.52 x SPX):         ~+5%
  Nitrogen-cycle factor:            ~+45%
  Hormuz-blockade factor:           ~+20%
  Natural-gas-spread factor:        ~+5%
  Idiosyncratic alpha:              ~+7%  ← product mix, buybacks, CCS

The apparent "stock pick" is overwhelmingly factor exposure. Nitrogen-cycle and Hormuz account for roughly 65 percentage points of the +82% return. True idiosyncratic variance is 50-65% of total, below the 75% target. CF loads 0.5 on the Hormuz factor alongside UAN, LXU, NTR, and MOS. Buying CF for Hormuz is buying a factor ETF at active-management fees. LXU ($488M cap, minimal coverage) offers more mispricing potential per dollar of nitrogen-factor exposure.

Business Model (B)

What CF Actually Makes

CF is a natural gas converter. Haber-Bosch chemistry (1909) converts pipeline methane into ammonia. No proprietary science, no patents, no product differentiation. The molecule is a commodity.

CH₄ + H₂O → H₂ + CO₂    (steam methane reforming)
N₂ + 3H₂ → 2NH₃          (Haber-Bosch)

Ammonia is sold directly or upgraded to urea ($433/ton, solid fertilizer), UAN ($311/ton, liquid spray), ammonium nitrate ($317/ton, fertilizer + explosives), and DEF ($262/ton, diesel emissions). Revenue is 100% price-driven at capacity. At 97% utilization and 10.1M gross ammonia tons, CF is capacity-constrained. Revenue growth = nitrogen price growth. Volume contribution was +1% in FY2025 vs +19% from ASP.

Conversion Economics

From the 10-K: 350M MMBtu consumed / 10.1M tons produced = ≈34.7 MMBtu per ton ammonia. Gas = ≈27% of total cost of sales (≈$1.16B on $4.36B COS).

Even with gas doubled, CF retains a $197/ton cost advantage over the European marginal producer that sets global prices. That spread IS the toll booth.

Gas sensitivity by product (10-K): $1/MMBtu increase = $32/ton ammonia, $22/ton urea, $14/ton UAN. UAN is the least gas-intensive product -- which is exactly why management shifted production there when gas rose.

Product Flexibility

Management deliberately shifted Donaldsonville production from urea to UAN in FY2025 (urea volume -9%, UAN +3%) to capture higher UAN margins (+48% GM/ton improvement from $90 to $133). Single-product competitors (CVR Partners = UAN only) cannot do this. This operational discipline generated ≈$150-200M incremental gross margin versus a static product mix.

Revenue Decomposition (FY2025)

Approximately 75-80% agricultural, 20-25% industrial (DEF, explosives, chemical intermediates). ≈85-90% North American revenue.

The Toll Booth Mechanism

Management quantified the Hormuz exposure on the Q4 2025 call (Frost, SVP Sales):

• 35% of ocean-traded urea transits Hormuz (≈20M tons from Iran/Oman/Qatar/Saudi/UAE)
• 30% of ocean-traded ammonia (≈5M tons)
• 25% of global LNG

When that supply is at risk, global nitrogen prices spike to European marginal cost ($12-15/MMBtu gas). CF produces at $3-6/MMBtu gas. The spread widens. The cost pass-through is asymmetric:

• $3/MMBtu US gas increase → ≈$475-600M incremental annual cost
• But nitrogen price uplift → $1.1-1.9B revenue gain
• 3.4:1 price-to-gas-cost leverage ratio (FY2025 margin bridge: +$1,064M price vs -$316M gas cost)

Spring planting (99M acres corn, USDA) makes demand perfectly inelastic over the next 60 days.

Management deliberately runs unhedged (only 2% of gas consumption covered by derivatives, 13.5M MMBtu in basis swaps). This is a conscious strategic bet, not negligence -- higher NA gas pushes global prices up, and CF wins on the ratio.

Resource Base and Replacement Cost

CF doesn't own gas. It's a converter, not an extractor. Pipeline connections to 9 hubs. Consumption: 350M MMBtu/year = <0.001% of US gas production. No resource constraint. "Reserve life" is infinite -- the resource is the gas price differential, not the gas itself.

EV/Replacement Cost: 0.63-0.87x. Below replacement cost. No rational actor builds new capacity when existing capacity is cheaper in the stock market. The distribution network is hardest to replicate -- 39 terminal leases, 5,000 railcar contracts, Sunoco pipeline access, river barge fleet. Decades of commercial relationships.

Financial Trajectory (Phi)

Margin Bridge (FY2025 vs FY2024)

• Price uplift: +$1,064M
• Gas cost increase: -$316M ($3.31/MMBtu vs $2.40/MMBtu)
• Manufacturing/maintenance: -$115M
• Net: +$633M gross margin improvement

By segment, UAN was the biggest contributor (+$312M, +51%), driven by ASP increase (+$424M) partially offset by gas (-$99M) and manufacturing (-$34M). Granular urea added +$163M despite -9% volume, purely on pricing (+$315M). Ammonia added +$189M from both price (+$246M) and volume (+$118M from Waggaman yield). AN was flat (Yazoo City idling offset pricing gains).

Gas Cost -- The Forward Headwind

Henry Hub averaged $3.31 in FY2025; Jan-Feb 2026 realized $6.32/MMBtu. On 350M MMBtu consumption, that's ≈$1.05B incremental annual gas cost. The 3.4:1 ratio suggests price offsets overwhelm the cost -- but this ratio was measured during gradual increases. A sharp spike could compress it if nitrogen prices lag.

Forward gas strip was $3.00-3.50 at the time of Q4 call. Current realized is nearly double. If HH sustains above $5.00 through FY2026, this is the single largest headwind to earnings -- partially offset but not fully eliminated by nitrogen price pass-through.

Capital Allocation

Shares outstanding: 188M → 170M → 154M in two years. 21% reduction. $1.7B remaining authorization through Dec 2029 under the 2025 program.

Mechanical EPS support: FY2025 diluted EPS was $8.97 on 162.2M diluted shares. Same earnings on 145M shares (2027 est) = $10.05. That's a 12% EPS lift from buybacks alone. The Orica settlement ($169.5M one-time cash, 8-K Mar 16 2026) funds additional repurchases.

Capex ramping: $518M (FY2024) → $950M (FY2025) → $1.3B (FY2026 guidance). Breakdown of 2026:

• Existing operations: ≈$550M (maintenance)
• Blue Point JV construction: ≈$600M ($240M CF share / 40%; partners fund $360M / 60%)
• Blue Point scalable infrastructure: ≈$150M (CF owns and operates)

Balance Sheet

All debt is unsecured senior notes maturing 2034-2044. Nov 2025 issued $1B 5.30% due 2035; Dec 2025 redeemed $750M 4.50% due 2026. Net increase +$250M. Interest coverage ≈15x. No refinancing risk for a decade.

Working Capital

Net working capital was $200M less favorable for cash flow in FY2025 vs FY2024. AR increased $84M (higher selling prices), inventory increased $69M (higher gas costs in COGS + seasonal build), customer advances declined $41M (timing of UAN programs).

45Q Tax Credits

$42M earned in H2 2025 from Donaldsonville CCS (≈700K tons CO2 sequestered). Targeting 1.5M metric tons in 2026, implying ≈$128M annualized. By end of decade: Donaldsonville + Yazoo (when online) + Verdigris abatement = $150-200M/year in ratable, price-independent income.

Risk: "proposed repeal of GHG emissions reporting obligations could delay or eliminate our ability to realize anticipated tax credits" (10-K risk factors).

Competitive Position (K)

Moat Classification: K_scale (cost advantage). Strong but narrow.

CF does not set prices. The 10-K states competition is "based primarily on delivered price" with "limited barriers to entry" (line 955-959). This is a commodity with zero product differentiation.

But CF is the dominant low-cost producer:

1. World's largest ammonia complex (Donaldsonville, 4.335M gross tons).

2. ≈40% of NA ammonia capacity. Also ≈41% urea, ≈44% UAN, ≈19% AN. HHI ≈2,628 (highly concentrated oligopoly). CF + Nutrien + Koch = ≈80%.

3. $7-8/MMBtu structural gas cost advantage over European marginal producers. Even at $6.32 HH: $197/ton advantage over $12/MMBtu TTF producers.

4. Distribution network as soft moat. 39 terminals across 17 states, 5,000 railcars, 13 tow boats, 42 barges, Sunoco ammonia pipeline access. Delivered cost to an Iowa cooperative is ≈$30/ton below import parity (Frost, Q3 2025). 2.8M tons aggregate storage.

Switching Cost (φ)

Zero on product (nitrogen is nitrogen). Moderate on delivery. For a hypothetical Iowa cooperative buying 50,000 tons/year of UAN: φ_logistics ≈ $30/ton × 50K tons = $1.5M/year implicit switching cost. φ_product = $0.

CHS Relationship

Largest customer (13% of net sales) owns ≈11% of CFN (the subsidiary holding 5 of 6 US plants). Supply agreement for ≈1.7M tons/year (1.1M urea + 580K UAN) at market prices. CHS receives semi-annual distributions from CFN. Equity-aligned, not arm's-length.

European Competition: Structurally Declining

Bohn (Q4 2025): European ammonia plants shrunk from 48 to ≈30-31, with another 4-5 closures expected. TTF at $10-12/MMBtu makes most plants economic only 3-4 months/year. CF itself closed Ince (UK) in 2022 and ceased Billingham ammonia in 2023.

NATO allies unlikely to resume Russian gas imports. EU tariffs on Russian nitrogen began July 2025. This is structural, not cyclical.

China Risk

Chinese urea exports ≈3-5M tons/year under government restriction. Management views as manageable. But the 10-K warns: "Changes in Chinese government policy, higher utilization of production capacity, devaluation of RMB, relaxation of environmental standards, or decreases in coal costs could encourage expanded exports." This is the tail risk.

Market Share Trajectory: Growing

• Waggaman acquisition (2023): +880K tons
• Blue Point JV (2029): +1.5M tons at Modeste, LA
• Blue Point site can hold "up to 5 ammonia plants" (Bohn, Q4 2025) -- organic growth platform
• European exits tightening global supply

Clean Ammonia -- The CCS Technology Layer

Existing (Donaldsonville CCS, operational July 2025):

• Bolt-on CO₂ capture to existing SMR. Captures ≈60% of process CO₂.
• 1.9M tons/year certified low-carbon ammonia -- "largest in the world" per management.
• ExxonMobil/Denbury transports and sequesters CO₂.
• First sales of certified low-carbon ammonia at a premium (Frost, Q3 2025).
• CBAM (EU, Jan 2026) and UK carbon border mechanism (Jan 2027) create export advantage.

Future (Blue Point ATR, production 2029):

• Autothermal reforming captures >95% of CO₂ (vs 60% for SMR+CCS).
• 10-K flags: "ATRs have not been widely used for ammonia production and not at the scale contemplated" (line 2745-2747). Technology risk.
• 1.4M metric tons ammonia/year, capturing 2.3M metric tons CO₂.
• Budget: $3.7B ($500M contingency intact). Partners fund 60%.
• JERA (35%, locked in, option expired) + Mitsui (25%) provide offtake and capital.
• Japanese government providing "contract for difference" awards for clean ammonia.
• Linde contracted June 2025 for air separation unit.

Abandoned: 20-MW electrolyzer at Donaldsonville. $51M impairment. Industry pivoting from green (45V) to blue (45Q). One Big Beautiful Bill Act validated this choice.

Governance (G)

The Regime Change

CEO Will retired Jan 4, 2026 after 12 years. CFO Cameron "mutually agreed to separate" Jan 5, 2026 (8-K Jan 7), effective Feb 15. Two C-suite departures in six weeks is not routine succession -- it's a board-driven reset. "Mutually agreed to separate" is the language companies use when the board wants someone gone but doesn't want to trigger cause-based provisions.

CEO Bohn (former COO) elevated. EVP Menzel received $2.5M retention RSU -- board worried about cascade. Interim CFO Hoker is a 19-year CF veteran (VP/Controller since 2007). External search for permanent CFO commenced.

Insider Activity: Unambiguously Selling

Will liquidated ≈40% of pre-retirement holdings (233K shares) at $100-136 within 6 weeks. He's not waiting to see how Bohn performs. All via Form 144 (pre-planned 10b5-1).

Total D&O ownership: 781,578 shares across 21 persons (< 1% of 153.6M outstanding). Bohn holds 142,963 shares (≈$18.6M at current price). No director or officer has meaningful skin in the game relative to their net worth.

Compensation Structure

Annual Incentive Plan (AIP):

• Adjusted EBITDA: 60% weight. FY2025 target $2.1B, actual $2.88B → maximum payout.
• Clean Energy Milestones: 20% weight. Achieved 5 of 3 targeted → maximum.
• Process Safety: 20% weight. 99.4% behavioral gate, 99.9% completion → maximum.
• FY2025 AIP: 200% of target. CEO received $4.2M on $2.1M target.

Long-Term Incentive (LTIP):

• 60% PRSUs: RONA-based (3-year average) × TSR modifier (±20%).
• 40% RSUs: Time-vesting, 3-year cliff.
• FY2025 RONA: 31.8% → 200% base payout.
• 3-year TSR: -11.7% → 80% modifier (maximum downward adjustment).
• Combined: 200% × 80% = 160% of PRSU target. The modifier caught underperformance. System working.

CEO target comp: $11.5M ($1.4M salary + $2.1M AIP target + $8.0M LTIP). 88% at-risk.

Weakness: Absolute TSR modifier, not relative. Board claims "insufficient peer comparators" -- debatable given NTR, MOS, and Yara exist. In strong markets, this pays regardless of relative performance.

94% say-on-pay approval. CEO pay ratio: 88:1 (moderate for S&P 500 industrial; median ≈186:1 per Equilar).

Board

11 nominees, 10 independent (91%). Separate independent Chair (Hagge). All committee chairs independent. Mandatory retirement policy. 5x retainer stock ownership requirement. Anti-hedging and anti-pledging policies. Clawback policy.

Golden parachute shareholder proposal on 2026 ballot. Board recommends against. But its presence signals institutional concern about severance protections during the transition.

ROIC vs WACC

Even in trough year (FY2024), ROIC was 2.7x WACC. WACC calculation: 7.1% cost of equity (4.5% risk-free + 0.52 × 5.0% ERP) × 58% weight + 3.9% after-tax cost of debt × 42% weight = 5.8%.

Institutional Ownership

Factor Profile (Beta)

Observed Metrics

Latent Factor Decomposition

A simple SPY regression shows ≈5% market variance and ≈95% "idiosyncratic." But this is an artifact of latent factors:

True idiosyncratic share: 50-65%. Below the 75% target. The nitrogen-cycle, Hormuz, and gas-spread factors are shared across CF, UAN, LXU, NTR, and MOS. Any "alpha" from buying CF for Hormuz is factor exposure masquerading as stock selection.

Normalized Valuation

Trailing P/E of 14.5x flatters because earnings are cyclically elevated. Mid-cycle EPS of ≈$6-7 (management's $2.5B EBITDA at $3.50 gas → ≈$1.0B net income → ≈$6.50/share on 154M shares) implies normalized P/E of 19-22x. EV/mid-cycle EBITDA of 8.5x is upper-half of chemical company range (6-9x). Not cheap. Not egregiously expensive.

Options Structure -- Floor/Ceiling Map

Three expirations dominate: Apr 17 (43,601 OI), Jun 18 (21,934), May 15 (13,247).

Ceiling (call walls = resistance):

Floor (put walls = support):

Max pain path -- DOWN:

Apr 10:  $130   (pinned at spot)
Apr 17:  $125   (-3.8%)
Jun 18:  $115   (-11.5%)
Sep 18:  $120   (-7.7%)

The Apr 17 cliff. On Apr 17, both ceiling (13,638 call OI at $130-145) and floor (3,047 put OI at $125) vanish simultaneously. Stock enters a structural vacuum. Next support is Jun 18 at $105-115 -- a 12-19% air pocket below current spot. Earnings (May 6) fall in this vacuum. Stock will be structurally unsupported during the most important catalyst of the quarter.

Institutional positioning: May 15 P/C 0.30 (euphoric -- retail buying calls for earnings breakout). Jun 18 P/C 1.28 (bearish -- the only bearish expiry). Institutions are hedged at $105-115 through summer while retail bought calls. Sep 18 unusual put activity at $82 (3.1x vol/OI) and $98 (2.1x vol/OI) -- someone pricing 25-37% downside through September.

Q → P adjustment: β = 0.52, SR_market ≈ 0.4. By Jun 18 (72 days): real-world downside probability is ≈4% higher than options-implied. By Sep 18 (164 days): ≈6% higher. Market is more bearish than the chain quotes.

Expectations Gap (Delta)

Price-Implied Parameters

g = -17% EPS decline* from $8.97 to $7.41. Street prices nitrogen price reversion + elevated gas costs. Revenue reverts toward $6.0-6.5B with margins compressing to 26-28% operating.

m = 26-28% operating margin* at mid-cycle. EV/mid-cycle EBITDA of 8.5x ($21.3B / $2.5B). Upper-half of chemical company range -- some quality premium but no clean ammonia optionality premium.

d = perpetuity with slight fade.* Implied growth -1.2%. Market prices the cost advantage as permanent (correct) but sees no structural volume growth (also correct -- production capped at ≈19M product tons).

Gap Ranking

The gap structure is unfavorable. The only large gap (Hormuz premium) is factor-level and consensus. The stock-specific gaps (45Q, buyback, Orica) are individually small. Nothing sits in the upper-left quadrant of "large AND specific" where tradeable alpha lives.

Mispricing Actionability

Each gap assessed for: magnitude, evidence quality, identifiable catalyst, timeline to convergence, and forcing function.

Hormuz (#1): Large but not actionable at stock level. This is a nitrogen-factor bet shared across all names. The $33 gap between stock price and consensus means the market figured it out before sell-side updated models. Not edge -- sell-side latency. After spring planting ends (June), demand becomes elastic and the premium compresses regardless.

45Q credits (#3): Stock-specific and growing, but no catalyst. Credits accrue quarterly, not as a step function. Policy risk is real and binary (GHG reporting repeal). Blue Point 2029 production is beyond forecast horizon. A gap that closes over 3-5 years through quarterly accruals is not a trade -- it's a multi-year hold thesis at a better entry price.

Orica (#5): Mechanical Q1 beat (≈$0.85/share one-time vs $2.47 consensus). But one-time, non-recurring, immediately identified as such. On a stock at +82%, marginal buyers aren't looking for one-time gains. Risk/reward on earnings trade is asymmetric the wrong way at $130.

Primary Source Audit

Risk Factors -- New/Changed vs Prior Year

1. Yazoo City incident -- NEW. Production offline until Q4 2026 "at the earliest." $25M impairment. Investigation ongoing. Insurance coverage NOT quantified in 10-K.
2. Electrolyzer abandonment -- NEW. $51M impairment. Clean pivot from 45V to 45Q.
3. Tariff disclosure -- NEW AND EXTENSIVE. Supreme Court IEEPA ruling, 10% tariff on most imports, ammonia NOT exempt (but Canadian production is). Steel/aluminum tariffs may raise Blue Point construction costs.
4. EU CBAM -- NEW. Implementation began Jan 2026. Creates regulatory advantage.
5. One Big Beautiful Bill Act -- NEW. Limited 45V credits. Validated CCS pivot.
6. GHG reporting repeal risk -- NEW. Threatens 45Q credits.
7. PLNL gas contract expiration -- UPDATED. NGC contract expired Jan 1, 2026. Short-term extensions only. Carrying value $32M (immaterial).

Counterparty Audit

Steelman Bear Case

The strongest argument against CF at $130: you're buying a consensus factor trade at peak momentum with regime-change governance risk.

1. The toll booth premium is fully capitalized. Stock moved from $72 to $142. The ≈$58/share move prices ≈$600-700M incremental annual profit from Hormuz. With urea at $664/MT, the market has already done the math. Twenty-one analysts. Every ag/energy desk has this trade. Edge = P_you - P_market. At $20B market cap with full coverage, P_you = P_market.

2. Hormuz resolution is binary and unknowable. If the Strait reopens, 35% of ocean-traded urea and 30% of ammonia re-enter the market. Nitrogen prices revert to mid-cycle. At $2.5B mid-cycle EBITDA and 8.5x multiple, EV stays ≈$21.3B -- but with momentum unwind and multiple compression, the stock overshoots to the downside. The FY2022-2024 analog: $142 to $71 in 24 months as Russia/Ukraine fertilizer premium unwound.

3. Two C-suite departures during the most volatile nitrogen market in years. Cameron was pushed out. Will is liquidating 40% of holdings at speed. The new CEO is untested. Capital allocation discipline matters most right now ($1.3B capex, $1.7B buyback authorization, Hormuz P&L volatility) and the leadership team is in transition.

4. The 3.4:1 leverage ratio may not hold at $6.32 gas. Measured during FY2025 at $3.31 average. At double the gas cost, nitrogen prices need proportional uplift. If gas spikes faster than nitrogen prices adjust -- or if Hormuz deescalation drops nitrogen prices while gas stays elevated -- margins compress.

5. Normalized valuation is not cheap. Trailing P/E of 14.5x flatters. Normalized P/E on $6-7 mid-cycle EPS is 19-22x. The "value" screen is a cyclical illusion.

6. Options plumbing confirms the bear. Max pain path DOWN ($130 → $125 → $115). Jun 18 is the only bearish P/C (1.28). Institutions hedged while retail speculated. Apr 17 removes both ceiling and floor -- earnings happen in a structural vacuum. Sep 18 unusual put activity prices 25-37% downside.

This bear case is not dismissed by the bull evidence. It's the other side of the same evidence viewed honestly.

Kill Criteria

Thesis dies if (bear triggers):
- Hormuz resolution announced → nitrogen prices revert to pre-disruption
  levels within 60 days. Factor premium unwinds. CF reverts toward $95-100.
- Q1 2026 operating margins < 28% (vs 32.5% FY2025) → gas cost leverage
  ratio breaking down. The toll booth has a crack.
- Blue Point budget overrun > $500M contingency → CF's $1.5B share inflates,
  compressing FCF available for buybacks.
- Chinese urea export policy relaxation → 5-10M incremental tons flood global
  market. Structural deficit thesis invalidated.

Thesis strengthened if (bull triggers):
- Hormuz escalation extends through Q3 with no resolution →
  sustained premium longer than market expects.
- 45Q credits > $150M annualized by Q4 2026 →
  ratable income stream gaining materiality.
- Permanent CFO hire is strong external candidate →
  governance premium restored.
- European plant closures accelerate beyond 4-5 additional →
  structural supply tightening confirms.

What to Watch

1. Q1 2026 earnings (May 6). First quarter under new CEO Bohn. Gas cost realization at $6.32 vs FY2025 $3.31. Does the 3.4:1 leverage ratio hold? Orica settlement recognition ($0.85/share). Yazoo restart timeline. Forward guidance tone from untested management.

2. Options expiry Apr 17. 43,601 OI. Ceiling at $130-145 and floor at $125 both vanish simultaneously. Stock enters structural vacuum through earnings. Volatility should increase.

3. Henry Hub forward strip. If gas normalizes toward $3.50-4.00, margin pressure eases. If sustained above $5.00, watch for ratio compression.

4. Hormuz headlines. Any diplomatic resolution or military escalation reprices the entire nitrogen complex overnight. This is the dominant factor.

5. Permanent CFO announcement. External hire = board reset confirmed. Internal = less drama than feared.

6. Blue Point permitting. Air permit and Army Corps permit next. Civil work expected Q2 2026. Any delays compress the 2029 production timeline.

7. Chinese export policy. Any signal of relaxation changes the structural nitrogen thesis.

LR Signal

LR = 0.8 (mild bearish).

The analysis confirms the toll booth mechanism is real and quantified. But the market has already priced it. The stock sits 36% above consensus at +82% momentum. Insiders are selling $27M. Governance is in transition. True idiosyncratic share (50-65%) is below the 75% threshold. Options structure shows max pain path down with institutional hedging.

The single most important finding: what appears to be stock-specific alpha is nitrogen-cycle and Hormuz factor exposure available more cheaply through the complex. The market isn't wrong about CF being a Hormuz beneficiary -- it's right. The edge question is whether you're paying a fair price for that factor exposure, and at $130 vs $96.68 consensus, the answer leans no.

This is not a strong bearish signal -- the company is genuinely excellent (ROIC 19.7%, fortress balance sheet, 21% share reduction in 2 years, below replacement cost). The mild bearish tilt comes from valuation and positioning, not business quality.

Evidence